Medical imaging software and services provider MEDIAN Technologies has chosen
Microsoft’s Big Data services for its cancer diagnostics requirements. MEDIAN Technologies, which has headquarters in Sophia-Antipolis, France, was established in 2002. The company focuses on supporting oncology clinical trials, cancer screening, and clinical practice through standardizing and automating the interpretation of medical images to optimize cancer diagnoses. It has a US subsidiary in Boston, United States and has a presence in Asia, Europe, North and South America, and Australia.
Median Technologies’ deal with Microsoft will see a merging of its proprietary ‘Ibiopsy’ imaging biomarker phenotyping system and Microsoft’s Azure cloud computing platform. Together the systems will “provide capabilities for processing and analyzing medical images and extracting biomarkers for cancer diagnosis and treatment”. Ibiopsy will be made available to medical facilities and physicians in the United States, Europe and Asia at some stage in the future.
“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine,” explained Bernard Ourghanlian, the CTO of Mircosoft France in a press release. “We are proud to collaborate with Median on the Ibiopsy project and to bring innovative technologies at the service of cancer research. Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, Ibiopsy will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring.”
Do you know of any other companies collaborating? Let us know the details. Add your comments below.
